Avoro Life Sciences Fund LLC
Raised
$3.5B
Investors
292
Min Invest
$1,000,000
AltStreet Analysis
·Generated from EDGAR primary sources
Avoro Life Sciences Fund LLC is a Delaware pooled investment fund managed by Avoro Capital Advisors LLC. This amended filing reports $3.45 billion raised from 292 investors under Rule 506(b) and 3(c) exemptions, with a $1.0 million minimum investment. Executive officers include Behzad Aghazadeh, Scott Epstein, and Neil Cammarosano.
This is a substantial life sciences-focused pooled investment fund utilizing the 506(b) private placement exemption paired with 3(c) for investment company status. The $1.0 million minimum is consistent with institutional and qualified purchaser funds in the alternative investment space, and the capital raised places it in the upper tier of sector-focused alternative funds.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
- Avoro Capital Advisors LLC
Promoter · New York, NY
Behzad Aghazadeh
Executive Officer · New York, NY
Scott Epstein
Executive Officer · New York, NY
Neil Cammarosano
Executive Officer · New York, NY
- Avoro Capital GP, LLC
Promoter · New York, NY
- Avoro Capital L.P.
Promoter · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
